There are two types of narcolepsy, and both cause EDS. Most people with Type 1 (with cataplexy — the sudden loss of muscle tone explained above) have low levels of the brain hormone hypocretin ...
In addition to excessive daytime sleepiness, up to 60% of narcolepsy cases include cataplexy, which is a sudden loss of muscle control. When patients experience intense emotion, either positive or ...
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...
A narcolepsy service dog is a long term commitment. But having one can help you live a safer life by alerting you before a narcolepsy episode. They can also help with other daily tasks and provide ...
Neuraxpharm has acquired these products in most markets outside the US^. Provigil's main market is Europe, with significant sales in France, Spain and Italy. Nuvigil is present in international ...
On October 16, 2024, LUMRYZ was additionally approved as a once-at-bedtime treatment for cataplexy or EDS in patients 7 years of age and older with narcolepsy. The FDA approval of LUMRYZ was ...
Samelisant (SUVNG-3031) is under development for the treatment of narcolepsy with and without cataplexy and cognitive disorders. The drug candidate is administered orally in the form of tablet. The ...
On October 16, 2024, LUMRYZ was additionally approved as a once-at-bedtime treatment for cataplexy or EDS in patients 7 years of age and older with narcolepsy. The FDA approval of LUMRYZ was supported ...